Loading company…
SphingoTec develops in vitro diagnostic tests based on blood protein biomarkers for kidney, sepsis and heart failure in acute care.
Founded in 2013 and headquartered in Hennigsdorf, Germany, SphingoTec GmbH develops in vitro diagnostic products based on proprietary blood-based protein biomarkers. Its CE IVD microtiter plate assays, including penKid, target critical and acute care settings such as acute kidney injury, sepsis and acute heart failure, and are sold to hospitals, laboratories and pharmaceutical companies. The company closed EUR 5 million in Series C funding on July 25, 2024, led by Think.Health Ventures, with a current valuation of EUR 8.646 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in